(Q24673072)

3

0 references

author name string

A Barber

2

0 references

J Del Río

4

0 references

M Martin-Martínez

5

0 references

I Gómez-Monterrey

6

0 references

R Herranz

7

0 references

R González-Muñiz

8

0 references

M T García-López

British Journal of Pharmacology

9

0 references

language of work or name

English

0 references

publication date

June 1997

0 references

published in

0 references

volume

121

0 references

issue

4

0 references

page(s)

759-67

0 references

cites work

Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

The inhibitory action of noradrenaline and adrenaline on acetylcholine output by guinea-pig ileum longitudinal muscle strip

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

The binding site for [3H]glibenclamide in the rat cerebral cortex does not recognize K-channel agonists or antagonists other than sulphonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Anxiolytic effects of CCK-B antagonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Long-lasting neurochemical and functional changes in rats induced by neonatal administration of substance P antiserum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

The CCK-A receptor antagonist, devazepide, blocks the anorectic action of CCK but not peripheral serotonin in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Distinct cholecystokinin receptors in brain and pancreas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Interaction of CCK with pancreatic acinar cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Potency of L-364,718 as an antagonist of the behavioral effects of peripherally administered cholecystokinin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Species specificity of pharmacological characteristics of CCK-B receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

High affinity specific [3H] (+)PN 200-110 binding to dihydropyridine receptors associated with calcium channels in rat cerebral cortex and heart

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Two brain cholecystokinin receptors: implications for behavioral actions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

The peripheral cholecystokinin receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Evidence for an involvement of the brain cholecystokinin B receptor in anxiety

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Benzodiazepine receptors: Temperature dependence of [3H]flunitrazepam binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

A simple and reliable conflict procedure for testing anti-anxiety agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

CCK antagonists: pharmacology and therapeutic interest.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Cholecystokinin and regulation of pancreatic acinar cell function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021

Functional role of brain CCK receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701186

7 January 2021